Malignant ascites: Pathophysiology and treatment

International Journal of Clinical Oncology

Volumn 18, Issue 1, 2013, Pages 1-9

  Cavazzoni, Emanuel ^a   Bugiantella, Walter ^a   Graziosi, Luigina ^a   Franceschini, Maria Silvia ^a   Donini, Annibale ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Ascites; Carcinomatosis; Chemotherapy; Hyperthermic; Intraperitoneal; Malignant; Palliation; Paracentesis; Peritoneal

Indexed keywords

ALPHA INTERFERON DERIVATIVE; BATIMASTAT; BEVACIZUMAB; BLEOMYCIN; CATUMAXOMAB; CHLORMETHINE; CISPLATIN; DIURETIC AGENT; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 2 DERIVATIVE; MARIMASTAT; MITOMYCIN; PICIBANIL; RADIOISOTOPE; RECOMBINANT BETA INTERFERON; SPIRONOLACTONE; THIOTEPA; TUMOR NECROSIS FACTOR DERIVATIVE; VATALANIB;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILL; DEHYDRATION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; FEVER; HUMAN; HYPERKALEMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; INTESTINE DISTENSION; KIDNEY FAILURE; LAPAROSCOPY; MALIGNANT ASCITES; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PARACENTESIS; PATHOPHYSIOLOGY; PERITONEUM VEIN SHUNT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; TUMOR GROWTH; VOMITING;

ABDOMINAL NEOPLASMS; ASCITES; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOTHERAPY; LAPAROSCOPY; PALLIATIVE CARE; PARACENTESIS;

EID: 84874109246     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0396-6     Document Type: Review

References (71)

1. Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15(2):59-72 (review)
2. Saif MW, Siddiqui IA, Sohail MA (2009) Management of ascites due to gastrointestinal malignancy. Ann Saudi Med 29(5):369-377 (review)
3. Keen A, Fitzgerald D, Bryant A et al (2010) Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev (1):CD007794 (review)
4. Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198(6):999-1011 (review)
5. Zebrowski BK, Liu W, Ramirez K et al (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6(4):373-378
6. Brown PD (1995) Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35:293-301
7. Sharma S, Walsh D (1995) Management of symptomatic malignant ascites with diuretics: two case reports and a review of the literature. J Pain Symptom Manag 10(3):237-242 (review)
8. Lee CW, Bociek G, Faught W (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manag 16(2):96-101
9. Pockros PJ, Esrason KT, Nguyen C et al (1992) Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 103(4):1302-1306
10. Parsons SL, Watson SA, Steele RJ (1996) Malignant ascites. Br J Surg 83(1):6-14 (review)
11. Covey AM (2005) Management of malignant pleural effusions and ascites. J Support Oncol 3(2):169-173, 176 (review)
12. McNamara P (2000) Paracentesis - an effective method of symptom control in the palliative care setting? Palliat Med 14(1):62-64
13. Ginés P, Arroyo V, Quintero E et al (1987) Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 93(2):234-241
14. Ginès P, Titó L, Arroyo V et al (1988) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94(6):1493-1502
15. Salerno F, Badalamenti S, Incerti P et al (1987) Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 5(1):102-108
16. Quintero E, Ginés P, Arroyo V et al (1985) Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet 1(8429):611-612
17. Fleming ND, Alvarez-Secord A, Von Gruenigen V et al (2009) Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manag 38(3):341-349 (review)
18. Barnett TD, Rubins J (2002) Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach. J Vasc Interv Radiol 13(4):379-383
19. Rosenberg S, Courtney A, Nemcek AA et al (2004) Comparison of percutaneous management techniques for recurrent malignant ascites. J Vasc Interv Radiol 15:1129-1131
20. Stokes LS (2007) Percutaneous management of malignant fluid collections. Semin Interv Radiol 24(4):398-408. doi: 10.1055/s-2007-992328
21. Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42(5):589-597 (review)
22. Weisberger AS, Levine B, Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159(18):1704-1707
23. Appelqvist P, Silvo J, Salmela L et al (1982) On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol 20(4):238-242
24. Andersen AP, Brincker H (1968) Intracavitary thiotepa in malignant pleural and peritoneal effusions. Acta Radiol Ther Phys Biol 7(5):369-378
25. Groesbeck HP, Cudmore JT (1962) Intracavitary thio-TEPA for malignant effusions. Am Surg 28:90-95
26. Jones AL, Trott P, Cunningham D et al (1994) A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol 5(2):123-126
27. Markman M, Kelsen D (1992) Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118(7):547-550
28. Speyer JL, Collins JM, Dedrick RL et al (1980) Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40(3):567-572
29. Schilsky RL, Choi KE, Grayhack J et al (1990) Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 8(12):2054-2061
30. Kefford RF, Woods RL, Fox RM et al (1980) Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study. Med J Aust 2(8):447-448
31. Trotter JM, Stuart JFB, McBeth F et al (1979) The management of malignant effusions with bleomycin. Br J Cancer 40:310
32. Katano M, Torisu M (1982) Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50(1):62-68
33. Torisu M, Katano M, Kimura Y et al (1983) New approach to management of malignant ascites with a streptococcal preparation, OK-432. Improvement of host immunity and prolongation of survival. Surgery 93(3):357-364
34. Sherer DM, Eliakim R, Abulafia O (2000) The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 50(4):217-224 (review)
35. Stoelcker B, Echtenacher B, Weich HA et al (2000) VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res 20(5):511-517
36. Gebbia V, Russo A, Gebbia N et al (1991) Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. In Vivo 5(6):579-581
37. Katano M, Morisaki T (1998) The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 18(5D):3917-3925 (review)
38. Yamaguchi Y, Satoh Y, Miyahara E et al (1995) Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15(5B):2201-2206
39. Ariel IM, Oropeza R, Pack GT (1966) Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer 19(8):1096-1102
40. 32P) colloidal suspension therapy. Cancer 48(12):2596-2598
41. 131I radiotherapy. Br J Cancer 58(5):658-662
42. Buckman R, De Angelis C, Shaw P et al (1992) Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 47(1):102-109
43. Kobold S, Hegewisch-Becker S, Oechsle K et al (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12):1242-1251 (review)
44. El-Shami K, Elsaid A, El-Kerm Y (2007) Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol 25(18 Suppl):9043
45. Brown PD (1998) Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 52(1-3):125-136 (review)
46. Parsons SL, Watson SA, Steele RJ (1997) Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 23(6):526-531
47. Bramhall SR, Rosemurgy A, Brown PD, Marimastat Pancreatic Cancer Study Group et al (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19(15):3447-3455
48. King J, Zhao J, Clingan P et al (2003) Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 23(1B):639-645
49. Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36(6):458-467 (review)
50. Burges A, Wimberger P, Kümper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13(13):3899-3905
51. Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127(9):2209-2221
52. Garofalo A, Valle M, Garcia J et al (2006) Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 32(6):682-685
53. Knutsen A, Sielaff TD, Greeno E et al (2006) Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointest Surg 10(7):1038-1043
54. Facchiano E, Scaringi S, Kianmanesh R et al (2008) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34(2):154-158
55. Valle M, Van der Speeten K, Garofalo A et al (2009) Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100(4):331-334
56. Graziosi L, Bugiantella W, Cavazzoni E et al (2009) Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report. G Chir 30(5):237-239
57. Gesson-Paute A, Ferron G, Thomas F et al (2008) Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol 15(1):339-344
58. Chua TC, Yan TD, Saxena A et al (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249(6):900-907 (review)
59. Deraco M, Baratti D, Laterza B et al (2011) Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 37(1):4-9 (review)
60. Fagotti A, Paris I, Grimolizzi F et al (2009) Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 113(3):335-340
61. Kim JH, Lee JM, Ryu KS et al (2010) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 101(2):149-155
62. Kobold S, Hegewisch-Becker S, Oechsle K et al (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12):1242-1251 (review)
63. Elias D, Gilly F, Quenet F et al (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36(5):456-462
64. Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237-6242
65. Imamoto H, Oba K, Sakamoto J et al (2011) Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer 14(1):81-90
66. Oriuchi N, Nakajima T, Mochiki E et al (2005) A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol 35(7):386-390
67. Bellati F, Napoletano C, Gasparri ML et al (2011) Monoclonal antibodies in gynecological cancer: a critical point of view. Clin Dev Immunol 2011:890758
68. Hall M, Rustin G (2011) Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep 13(6):459-471 (review)
69. Tappenden P, Jones R, Paisley S et al (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 11(12):1-128, III-IV (review)
70. Garrett CR, Eng C (2011) Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 11(7):937-949 (review)
71. Dotan E, Meropol NJ, Burtness B et al (2012) A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer [Epub ahead of print]